Almirall SA · BME:ALM

Almirall SA — American Thoracic Society (ATS) Congress 2008

24 slides from Almirall SA's conference presentation, 2008

  1. Slide 1: Aclidinium bromide, a novel, long-acting anticholinergic in Phase III development for COPD

    Slide 1: Aclidinium bromide, a novel, long-acting anticholinergic in Phase III development for COPD

    Aclidinium bromide, a novel, long-acting anticholinergic in Phase III development for maintenance treatment of COPD Data presented at the American Thoracic Society (ATS) 2008 Per-Olof Andersson Executive Director, Research & Development Almirall, Barcelona, Spain Lawrence S. Olanoff President and Ch

  2. Slide 2: Aclidinium bromide data presented at ATS 2008: preclinical posters

    Slide 2: Aclidinium bromide data presented at ATS 2008: preclinical posters

    Aclidinium bromide data presented at the American Thoracic Society (ATS) Congress 2008 4 preclinical and 4 clinical presentations 4 preclinical posters 1. In vitro characterization of aclidinium bromide, a novel long-acting anticholinergic: effects on isolated human bronchi 2. Aclidinium bromide, a

  3. Slide 3: Aclidinium bromide data presented at ATS 2008: clinical posters

    Slide 3: Aclidinium bromide data presented at ATS 2008: clinical posters

    Aclidinium bromide data presented at the American Thoracic Society (ATS) Congress 2008 4 clinical posters 5. Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects 6. Low systemic exposure to aclidinium bromide, a novel long-acting antich

  4. Slide 4: Conclusions: ATS 2008 preclinical presentations

    Slide 4: Conclusions: ATS 2008 preclinical presentations

    Conclusions: ATS 2008 preclinical presentations z Aclidinium is a potent anticholinergic that has a long-lasting action in vitro and in vivo z This profile suggests that in the clinical setting aclidinium may provide sustained bronchodilation suitable for once-daily dosing z Aclidinium is rapidly hy

  5. Slide 5: Presentation 5: Pharmacokinetics and safety in healthy subjects

    Slide 5: Presentation 5: Pharmacokinetics and safety in healthy subjects

    Presentation 5: Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects P Ferrer,1 JM Jansat,2 E Garcia Gil2 1Centre Hospitalier de la Polynésie française, Papeete, French Polynesia 2Almirall, Barcelona, Spain

  6. Slide 6: Objectives

    Slide 6: Objectives

    Objectives 5 z This Phase I, placebo-controlled study assessed the pharmacokinetics, safety, tolerability, and maximum tolerated dose (MTD) of single doses of aclidinium in healthy male subjects | MTD was defined as the highest dose that does not cause at least 50% of subjects to experience function

  7. Slide 7: Aclidinium well tolerated at 600-6000 µg

    Slide 7: Aclidinium well tolerated at 600-6000 µg

    Results summary 5 z Aclidinium in the dose range of 600-6000 µg was well tolerated z No AEs were judged to be treatment related for doses up to 1800 µg | AEs were mild to moderate in severity and the overall incidence for aclidinium was comparable to placebo | There were no serious AEs z The MTD cou

  8. Slide 8: Aclidinium detectable in plasma only up to 1 hour post-dose

    Slide 8: Aclidinium detectable in plasma only up to 1 hour post-dose

    Results summary 5 cont z Aclidinium was only detectable in plasma up to 1 hour post-dose for the 600 µg, 1200 µg, and 1800 µg doses in the majority of subjects | This limited and transient systemic exposure suggests a low potential for anticholinergic systemic adverse events (intended clinical dose

  9. Slide 9: Presentation 6: Low systemic exposure after multiple doses

    Slide 9: Presentation 6: Low systemic exposure after multiple doses

    Presentation 6: Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses G de Miquel,1 A Schrödter,2 B Miletzki,2 M Gurniak,2 C Serra,1 JM Jansat1 1Almirall, Barcelona, Spain 2FOCUS Clinical Drug Development GmbH, Neuss, Germany

  10. Slide 10: Objectives

    Slide 10: Objectives

    Objectives 6 z This Phase I, randomized, placebo-controlled, single- blind, cross-over trial assessed the safety, tolerability, and pharmacokinetics of aclidinium 200-800 µg after multiple doses (5 consecutive days) were administered by dry powder inhaler in healthy subjects de Miquel et al, ATS 200

  11. Slide 11: Multiple doses well tolerated, low plasma levels

    Slide 11: Multiple doses well tolerated, low plasma levels

    Results summary 6 z Multiple doses of aclidinium (200-800 µg) were found to be well tolerated | This dose range studied was up to 4-times the anticipated therapeutic dose for COPD z Aclidinium 200 µg and 400 µg were undetectable in plasma z Aclidinium has a low potential for side effects resulting f

  12. Slide 12: Presentation 7: Aclidinium does not affect QT interval

    Slide 12: Presentation 7: Aclidinium does not affect QT interval

    Presentation 7: Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects KC Lasseter,1 J Aubets,2 E Garcia Gil2 1PharmaNet Development Group, Miami, FL, USA 2Almirall, Barcelona, Spain

  13. Slide 13: Objectives

    Slide 13: Objectives

    Objectives 7 z This Phase I, double-blind, randomized, parallel group study evaluated the effect on QT interval as well as overall cardiovascular safety of single and multiple doses of aclidinium 200 µg and 800 µg versus placebo and versus open-label moxifloxacin 400 mg daily in 272 healthy subjects

  14. Slide 14: No effect on QT interval versus placebo

    Slide 14: No effect on QT interval versus placebo

    Results summary 7 z Aclidinium, at doses up to 4-times (i.e. up to 800 µg) the therapeutic dose, demonstrated no effect on QT interval compared with placebo z ECG parameters were not affected by aclidinium administration z Aclidinium was well tolerated and no subjects withdrew due to adverse events

  15. Slide 15: Mean change in individual heart rate corrected QT interval

    Slide 15: Mean change in individual heart rate corrected QT interval

    Results summary 7 cont Mean change in individual heart rate corrected QT interval (QTci) in healthy subjects Aclidinium 200 µg, Day 1 Aclidinium 200 µg, Day 3 Aclidinium 800 µg, Day 1 20 Aclidinium 800 µg, Day 3 Mean change in QTci Moxifloxacin, Day 1 15 Moxifloxacin, Day 3 (msec) 10 5 0 -5 0 2 4 6

  16. Slide 16: Presentation 8: Once-daily aclidinium, Phase II dose-finding study

    Slide 16: Presentation 8: Once-daily aclidinium, Phase II dose-finding study

    Presentation 8: Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a Phase II, dose-finding study P Chanez,1 S Burge,2 R Dahl,3 J Creemers,4 R Lamarca,5 E Garcia Gil5 1Université de la Méditerranée AP-HM, Marseille, France 2Birmingham Heartlands Hospital, Birmingh

  17. Slide 17: Objectives

    Slide 17: Objectives

    Objectives 8 z This Phase II, double-blind, randomized, parallel group study assessed the efficacy, safety and tolerability of aclidinium compared with placebo in order to establish the optimal dose of aclidinium for use in Phase III studies z The study contained an open-label tiotropium treatment a

  18. Slide 18: Bronchodilatory effects sustained over 24 hours

    Slide 18: Bronchodilatory effects sustained over 24 hours

    Results summary 8 z Bronchodilatory effects of aclidinium were sustained over 24 hours z On Day 29, trough FEV1 was statistically significantly greater with aclidinium 200 µg, 400 µg and tiotropium 18 µg compared with placebo (primary endpoint) z On Day 1, aclidinium 100, 200 and 400 µg and tiotropi

  19. Slide 19: Results summary: mean change from baseline in trough FEV1

    Slide 19: Results summary: mean change from baseline in trough FEV1

    Results summary 8 cont Mean change from baseline in trough FEV1 on Day 29 Aclidinium Tio Placebo 25 µg 50 µg 100 µg 200 µg 400 µg 18 µg No. patients 64 65 65 69 66 67 64 LSMean, mL Ref. 39 36 83 148* 128* 161* 95% CI Ref. -67, 145 -70, 141 -22, 187 42, 253 22, 233 55, 267 LSMean = least squares mean

  20. Slide 20: Aclidinium significantly increased FEV1 over 6 h post-dose on Day 1

    Slide 20: Aclidinium significantly increased FEV1 over 6 h post-dose on Day 1

    Results summary 8 cont Aclidinium 100, 200 and 400 µg significantly increased FEV1 over 6 h post-dose on Day 1 Placebo Aclidinium 200 µg Aclidinium 25 µg Aclidinium 400 µg Aclidinium 50 µg Tiotropium 18 µg 300 Aclidinium 100 µg Least squares mean 250 FEV1 (mL) 200 150 100 50 0 0 1 2 3 4 5 6 Time pos

  21. Slide 21: Minimum effective dose of aclidinium was 100 µg

    Slide 21: Minimum effective dose of aclidinium was 100 µg

    Results summary 8 cont z The minimum effective dose of aclidinium in patients with moderate to severe COPD was 100 µg z Aclidinium 25-400 µg was well tolerated in patients with COPD in this study z Based on the results of this study, aclidinium 200 µg was selected for further development Chanez et a

  22. Slide 22: Conclusions: ATS 2008 clinical presentations

    Slide 22: Conclusions: ATS 2008 clinical presentations

    Conclusions: ATS 2008 clinical presentations z Phase I and II clinical studies consistently demonstrate that aclidinium produces bronchodilation for at least 24 hours z Aclidinium showed no effect on prolongation of QT interval z Aclidinium was well tolerated with minimal anticholinergic side-effect

  23. Slide 23: Aclidinium bromide: moving forward

    Slide 23: Aclidinium bromide: moving forward

    Aclidinium bromide: moving forward z Phase III trials on track, top-line results available second half of 2008 z Combination products development ongoing

  24. Slide 24: Thank you

    Slide 24: Thank you

    Thank you gS . G Almirall KB Forest Laboratories, Inc.

Source: Internet Archive copy of almirall.com

More decks from Almirall SA

All 39 Almirall SA decks